- /
- Supported exchanges
- / US
- / DSKYF.PINK
Daiichi Sankyo Company Limited (DSKYF PINK) stock market data APIs
Daiichi Sankyo Company Limited Financial Data Overview
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. It has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research. The company was founded in 1899 and is headquartered in Chuo, Japan.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue: 2 052 148 M
- EBITDA: 391 705 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Daiichi Sankyo Company Limited Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-05-11
- EPS/Forecast: 20.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-...
A Look At Daiichi Sankyo Company (TSE:4568) Valuation As Oncology Pipeline Drives Undervalued Thesis
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why Daiichi Sankyo Company (TSE:4568) is on investors’ radar today Daiichi Sankyo...
Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
Nuvation Bio, Inc. (NYSE:NUVB) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price more than doubled from a year ago, up 156.7%, while it registered a 40.79% i...
5 Best Small-Cap Biotech Stocks According to Hedge Funds
In this article, we will look at the 5 Best Small-Cap Biotech Stocks According to Hedge Funds. Please visit 10 Best Small-Cap Biotech Stocks According to Hedge Funds if you’d like to see an extended...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.